Xeris Pharmaceuticals (XERS) Stock Statistics & Valuation Metrics

Xeris Pharmaceuticals has a market cap or net worth of $1.07B. The enterprise value is $994.23M.

Xeris Pharmaceuticals has 172,642,060 shares outstanding. The number of shares has decreased by -2.65% in one year.

Xeris Pharmaceuticals’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 8.89%.

The current PE Ratio of Xeris Pharmaceuticals is 110.7. Xeris Pharmaceuticals’s PEG ratio is -22.52.

In the last 12 months, Xeris Pharmaceuticals had revenue of 291.85M and earned 554.00K in profits. Earnings per share was <0.01.

In the last 12 months, operating cash flow was 48.53M and capital expenditures -1.30M, giving a free cash flow of 47.23M billion.

Xeris Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Xeris Pharmaceuticals upcoming earnings date is Aug 6, 2026, Before Open (Confirmed).

Xeris Pharmaceuticals as a current ratio of 2.19, with Debt / Equity ratio of 286.90%

In the past 12 months, Xeris Pharmaceuticals has paid 0.00 in taxes.

Xeris Pharmaceuticals EV to EBITDA ratio is 93.32, with an EV/FCF ratio of 42.47.

Xeris Pharmaceuticals has $111.75M in cash and marketable securities with $37.33M in debt, giving a net cash position of $74.42M billion.

Gross margin is 81.59%, with operating margin of 8.53%, and net profit margin of 0.19%.

The average price target for Xeris Pharmaceuticals is $12.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy